Chemical Structure Differences Between Oxycodone and Hydrocodone
Oxycodone and hydrocodone differ by a single functional group: oxycodone has a ketone group at the C-6 position and a hydroxyl group at C-14, while hydrocodone has a ketone at C-6 but lacks the C-14 hydroxyl group.
Molecular Structure Details
Both medications are semi-synthetic opioids derived from thebaine (an opium alkaloid), but their chemical structures differ in clinically meaningful ways:
Oxycodone Structure
- Chemical name: 4,5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride 1
- Contains a hydroxyl (-OH) group at position 14 of the morphinan structure
- Has a ketone group at position 6
- Molecular characteristics: white, odorless crystalline powder with octanol-water partition coefficient of 0.7 1
Hydrocodone Structure
- Chemical name: 4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one (lacks the 14-hydroxyl designation)
- Does NOT have the hydroxyl group at position 14 that oxycodone possesses
- Also has a ketone group at position 6
- This single structural difference significantly impacts metabolism and pharmacokinetics 2
Clinical Implications of Structural Differences
Bioavailability
The C-14 hydroxyl group in oxycodone contributes to its superior oral bioavailability of 60-87% compared to hydrocodone 1. This structural difference reduces first-pass metabolism, making oxycodone more efficiently absorbed when taken orally.
Metabolic Pathways
The structural difference creates distinct metabolic profiles:
Oxycodone: Primarily undergoes N-demethylation via CYP3A4 to noroxycodone, with secondary O-demethylation via CYP2D6 to oxymorphone 1. The presence of the C-14 hydroxyl affects how these enzymatic reactions proceed.
Hydrocodone: Primarily undergoes N-demethylation via CYP3A4 to norhydrocodone, with O-demethylation via CYP2D6 producing hydromorphone 2. The absence of the C-14 hydroxyl group alters the metabolic pathway efficiency.
Receptor Activity
Oxycodone has agonist activity at mu-, delta-, AND kappa-opioid receptors 3, while hydrocodone acts primarily as a mu- and delta-opioid receptor agonist 3. This broader receptor profile for oxycodone may relate to its structural configuration.
Practical Considerations
Potency Differences
The structural variation translates to different equianalgesic dosing:
- Oxycodone: 15-20 mg oral dose equivalent to 10 mg parenteral morphine 3
- Hydrocodone: 30-45 mg oral dose equivalent to 10 mg parenteral morphine 3
This means oxycodone is approximately 1.5-2 times more potent than hydrocodone on a milligram-per-milligram basis, directly related to the structural differences affecting bioavailability and receptor binding.
Manufacturing Impurities
An important clinical caveat: hydrocodone can appear as an impurity (up to 1%) in oxycodone preparations 4, 5. This occurs because both drugs are synthesized from thebaine, and the similar structures mean small amounts of hydrocodone may remain in oxycodone products. When oxycodone urine concentrations exceed 100,000 ng/mL, hydrocodone should be <1,500 ng/mL; below 100,000 ng/mL oxycodone, hydrocodone should be <500 ng/mL 5. Values exceeding these thresholds suggest non-prescribed hydrocodone use rather than manufacturing impurity.